Neutralization of transforming growth factor β1 augments hepatitis C virus-specific cytotoxic T lymphocyte induction in vitro

Journal of Clinical Immunology

Volumn 17, Issue 6, 1997, Pages 462-471

  Kanto, Tatsuya ^a   Takehara, Tetsuo ^a   Katayama, Kazuhiro ^a   Ito, Akihiko ^a   Mochizuki, Kiyoshi ^a   Kuzushita, Noriyoshi ^a   Tatsumi, Tomohide ^a   Sasaki, Yutaka ^a   Kasahara, Akinori ^a   Hayashi, Norio ^a   Hori, Masatsugu ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Cytotoxic T lymphocytes; Hepatitis C virus; Interleukin 10; Transforming growth factor 1

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA2;

ARTICLE; CYTOLYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE INDUCTION; HEPATITIS C VIRUS; HLA SYSTEM; HUMAN; HUMAN CELL; LIVER DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RNA ANALYSIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADULT; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 15444340848     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1027367626317     Document Type: Article

References (30)

1. Kagi D, Ledermann B, Burki K, Zinkernagel RM, Hengartner H: Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol 14:207-232, 1996
2. Shirai M, Okada H, Nishioka M, Akatsuka T, Wychowski C, Houghton R, Pendleton CD, Feinstone S, Berzofsky JA: An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol 68:3334-3342, 1994
3. Battegay M, Fikes J, DiBisceglie AM, Wentworth PA, Sette A, Celis E, Ching WM, Grakoui A, Rice CM, Kurokohchi K, Berzofsky JA, Hoofnagel JH, Feinstone SM, Akatsuka T: Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 69:2462-2470, 1995
4. Koziel MJ, Dudley D, Afdhal N, Choo QL, Houghton M, Ralston R, Walker BD: Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in core and envelope proteins of HCV. J Virol 67:7522-7532, 1993
5. Massague J: The transforming growth factor-β family. Annu Rev Cell Biol 6:597-641, 1990
6. Sporn MB, Roberts AB: Transforming growth factor-β: Recent progress and new challenges. J Cell Biol 119:1017-1021, 1992
7. Castilla A, Prieto J, Fausto N: Transforming growth factor β1 and α in chronic liver disease. Effects of Interferon alfa therapy. N Engl J Med 324:933-940, 1991
8. Ruscetti F, Varesio L, Ochoa A, Ortaldo J: Pleiotropic effects of transforming growth factor-β on cells of the immune system. Ann NY Acad Sci 685:488-500, 1993
9. Lucas C, Bald LN, Fendly BM, Mora-Worms M, Figari IS, Patzer EJ, Palladino MA: The autocrine production of transforming growth factor-β1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA. J Immunol 145:1415-1422, 1990
10. Ota M, Seki T, Fukushima H, Tsuji K, Inoko H: HLA-DRB1 genotyping by modified PCR-RFLP method combined with group-specific primers. Tissue Antigens 39:187-202, 1992
11. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y and Muyumi M: Typing hepatitis C virus by polymerase chain reaction with type-specific, primers: Applications to clinical surveys and tracing infectious sources. J Gen Virol 73:673-679, 1992
12. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT, Chan SW, Chayamu K, Chen DS, Choo QL, Colombo M, Cuypers HM, Date T, Dusheiko GM, Esteban JI, Fay O, Hadziyannis SJ, Han J, Hatzakis A, Holmes EC, Hotta H, Houghton M, Irvinc B, Kohara M, Korberg JA, Kuo G, Lau J, Lelie PN, Maertens G, McOmish F, Miyamura T, Mizokami M, Nomoto A, Prince AM, Reesink HW, Rice C, Roggendorf M, Schalm SW, Shikata T, Shimotohno K, Stuyver L, Trepo C, Weiner A, Yap PL, Urdea MS: A proposed system for the nomenclature of hepatitis C virus genotypes. Hepatology 19:1321-1324, 1994
13. Sharrock CEM, Kaminski E, Man S: Limiting dilution analysis of human T cells: A useful clinical tool, Immunol Today 11:281-286, 1990
14. Borysiewicz LK, Graham S, Hickling JK, Mason PD, Patrick Sissons JG: Human cytomegalovirus-specific cytotoxic T cells: Their precursor frequency and stage specificity. Eur J Immunol 18:269-275, 1988
15. Tada T, Ohzeki S, Utsumi K, Takiuchi H, Muramatsu M, Li XF, Fujiwara H, Hamaoka T: Transforming growth factor-β-induced inhibition of T cell function. Susceptibility difference in T cells of various phenolypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 146:1077-1082, 1991
16. Fox FE, Ford HC, Douglas R, Cherian S, Nowell PC: Evidence that TGF-β can inhibit human T-lymphocyte proliferation through paracrine and autocrine mechanisms. Cell Immunol 150:45-58, 1993
17. Geller RL, Smyth MJ, Strobl SL, Bach FH, Ruscetti FW, Longo DL, Ochoa AC: Generation of lymphokine-activated killer activity in T cells. Possible regulatory circuits. J Immunol 146:3280-3288. 1991
18. Yamamoto H, Hirayama M, Genyea C, Kaplan J. TGF-β mediates natural suppressor activity of IL-2-activated lymphocytes. J Immunol 152:3842-3847, 1994
19. de Waal Malefyt R, Yssel H, Roncarolo MG, Spits H, de Vries JE: Interleukin-10. Curr Opin Immunol 4:314-320, 1992
20. Van-Vlasselaer P, Falla V, Van-Den-Heuvel R, Dasch J, de-Waal-Maletijt R: Interleukin-10 stimulates hematopoiesis in murine osteogenic stroma. Clin Orthop 313:103-114, 1995
21. Van-Vlasselaer P, Borremans B, van-Gorp U, Dasch JR, de-Waal-Maletijt R: Interleukin-10 inhibits transforming growth factor-beta synthesis required for osteogenic commitment of mouse bone marrow cells. J Cell Biol 124:569-577, 1994
22. Su HC, Kimberly A, Leite-Morris, Braun L, Biron CA: A role for transforming growth factor-β1 in regulating natural killer cell and T lymphocyte proliferative responses during acute infection with lymphocytic choriomeningitis virus. J Immunol 147:2717-2727. 1991
23. Bellone G, Aste-Amezaga M, Trinchieri G, Rodeck U: Regulation of NK cell functions by TGF-β1. J Immunol 155:1066-1073, 1995
24. Smyth MJ, Strobl SL, Young HA, Ortaldo JR, Ochon AC: Regulation of lymphokine-activated killer activity and poreforming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-β. J Immunol 146:3289-3297, 1991
25. Brown PD, Wakefield AD, Levinson AD, Sporn MB: Physico-chemical activation of recombinant latent growth factor-beta's 1,2,3. Growth Factors 3:35, 1990
26. Lyons RM, Keski-Oja J, Mosea HL: Proteolytic activation of latent transforming growth factor-β from fibroblast-conditioned medium. J Cell Biol 106:1659, 1988
27. Yoo YD, Ueda H, Park K, Flanders KC, Lee YIK, Jay G, Kim SJ: Regulation of transforming growth factor-β1 expression by the hepatitis B virus (HBV) × transactivator. Role in HBV pathogenesis. J Clin Invest 97:388-395, 1996
28. Minutello MA, Pileri P, Unutmaz D, Censini S, Kuo G, Houghton M, Brunello MR, Bonino F, Abrignani S: Compartmentalizalion of T lymphocytes to the site of disease: Intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med 178:17-25, 1993
29. Inge TH, Hoover SK, Susskind BM, Barrett SK, Bear HD: Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor β1. Cancer Res 52:1386-1392, 1992
30. Gorelik L, Bar-Dagan Y, Mokyr MB: Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells. J Immunol 156:4298-4308, 1996